Yuri Deigin (CEO of YouthBio Therapeutics) presents the case for partial cellular reprogramming as a path to reversing biological ageing. He explains how Yamanaka factors can reset the epigenetic clock in cells without causing dedifferentiation, the evidence from mouse studies showing lifespan extension and tissue rejuvenation, and the translation challenges toward human therapies. Deigin also covers the landscape of longevity biotech startups, the role of VitaDAO in funding pre-clinical research, and why decentralised science models are uniquely suited to longevity research with its long time horizons and diffuse IP.